WHO WE ARE
We are MediPrint™ Ophthalmics
An emerging San Diego-based clinical stage eye care pharmaceutical company developing and commercializing a proprietary ocular drug delivery portfolio focused on glaucoma, dry eye and ocular allergy initially.
We are using our proprietary MediPrint™ process to develop, clinically test and commercialize drug-eluting, comfort-enhancing contact lenses to treat millions of contact lens wearers worldwide, without the use of eye drops.
We plan to address a variety of eye care unmet needs, all with extensive market opportunities.
We aim to develop and commercialize a deep product pipeline, supported by strong intellectual property, with a highly experienced and successful execution team.
Our Mission
Our goal is to change the standard of care for successfully delivering ocular drugs to the eye non-invasively. We will use our patented MediPrint™ process to offer a unique value proposition for patients, eye care professionals, strategic partners and payers.
Our Vision
Enhancing vision for life.
Executive Summary
Clinical Stage Eye Care Pharmaceutical Company Focused on Helping Protect Sight
Compelling Unmet Need
40M+ Soft Contact Lens Wearers in the United States
Pipeline Established – Strong I.P.
Glaucoma, Dry Eye, Comfort, Allergy, …
SIGHT-1 Phase 2a Clinical Completed
Glaucoma, five patients, safety endpoints
Execution Team Secured
Clear Path to Exit
Phase 3 data in 18 months.